Shambavi Richard
Overview
Explore the profile of Shambavi Richard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, et al.
Blood Adv
. 2025 Mar;
PMID: 40088469
No abstract available.
2.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500453.
PMID: 40053892
No abstract available.
3.
Sanchez L, Richard S
Semin Hematol
. 2025 Feb;
PMID: 40021425
Despite the significant advancements in multiple myeloma therapy over the last decade, current unmet needs include populations of patients who continue to have inferior outcomes, such as those with high-risk...
4.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401730.
PMID: 39965175
Purpose: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety,...
5.
Ravi G, Richard S, Kumar S, Atrash S, Liedtke M, Kaur G, et al.
Leukemia
. 2025 Feb;
PMID: 39910285
BCMA-targeted CAR T-cells transformed the treatment of relapsed and refractory multiple myeloma (RRMM), yet improvements are needed in manufacturing, toxicity and efficacy. We conducted a phase 1 clinical trial of...
6.
Chen L, Thibaud S, Bodnar S, Chari A, Richter J, Cho H, et al.
Blood Adv
. 2024 Nov;
9(1):176-179.
PMID: 39546749
No abstract available.
7.
Galarza Fortuna G, Banerjee R, Savid-Frontera C, Song J, Moran-Segura C, Nguyen J, et al.
Blood Cancer J
. 2024 Oct;
14(1):180.
PMID: 39414769
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and...
8.
Avigan Z, Bodnar S, Pan D, Catlett J, Richter J, Sanchez L, et al.
Blood Adv
. 2024 Oct;
9(1):202-206.
PMID: 39383457
No abstract available.
9.
Thibaud S, Subaran R, Newman S, Lagana A, Melnekoff D, Bodnar S, et al.
Blood Cancer Discov
. 2024 Sep;
5(6):428-441.
PMID: 39283238
First-degree relatives of patients with multiple myeloma are at increased risk for the disease, but the contribution of pathogenic germline variants (PGV) in hereditary cancer genes to multiple myeloma risk...
10.
Richard S, Lesokhin A, Paul B, Kaufman J, Pianko M, Biran N, et al.
Nat Cancer
. 2024 Aug;
5(10):1459-1464.
PMID: 39187595
Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and...